Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Drug Profile

Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Alternative Names: BA 1016; BA 1037; BA 1049; BA 285; BA-1076; BA-207; BA-215; BA-240; Rhostatin™

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioAxone Therapeutic
  • Developer BioAxone Biosciences; BioAxone Therapeutic
  • Class Small molecules
  • Mechanism of Action Rho GTP-binding protein-inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cerebrovascular disorders; Spinal cord injuries
  • No development reported Glaucoma
  • Discontinued Cancer; Cancer metastases; Cardiovascular disorders; CNS trauma; Optic nerve disorders; Retinal disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glaucoma in USA
  • 15 May 2017 Preclinical trials in Spinal cord injuries in USA (unspecified route) (BioAxone BioSciences pipeline, May 2017)
  • 11 May 2017 BioAxone BioSciences plans to file an IND application for BA 1049 for Cerebral cavernous malformation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top